JPS61277620A - 排尿困難治療剤 - Google Patents

排尿困難治療剤

Info

Publication number
JPS61277620A
JPS61277620A JP61123220A JP12322086A JPS61277620A JP S61277620 A JPS61277620 A JP S61277620A JP 61123220 A JP61123220 A JP 61123220A JP 12322086 A JP12322086 A JP 12322086A JP S61277620 A JPS61277620 A JP S61277620A
Authority
JP
Japan
Prior art keywords
alfuzosin
dysuria
patients
therapy
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61123220A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0564930B2 (enExample
Inventor
フランソワ・レグニエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9319589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS61277620(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of JPS61277620A publication Critical patent/JPS61277620A/ja
Publication of JPH0564930B2 publication Critical patent/JPH0564930B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP61123220A 1985-05-28 1986-05-27 排尿困難治療剤 Granted JPS61277620A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8507950 1985-05-28
FR8507950A FR2582513B1 (fr) 1985-05-28 1985-05-28 Compositions pharmaceutiques contenant de l'alfuzosine

Publications (2)

Publication Number Publication Date
JPS61277620A true JPS61277620A (ja) 1986-12-08
JPH0564930B2 JPH0564930B2 (enExample) 1993-09-16

Family

ID=9319589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61123220A Granted JPS61277620A (ja) 1985-05-28 1986-05-27 排尿困難治療剤

Country Status (12)

Country Link
US (1) US4661491A (enExample)
EP (1) EP0204597B1 (enExample)
JP (1) JPS61277620A (enExample)
AU (1) AU586684B2 (enExample)
CA (1) CA1261755A (enExample)
DE (1) DE3683318D1 (enExample)
DK (1) DK168029B1 (enExample)
FR (1) FR2582513B1 (enExample)
HU (1) HUT46221A (enExample)
IE (1) IE58595B1 (enExample)
IL (1) IL78934A (enExample)
ZA (1) ZA863957B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694495B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Préparation pharmaceutique transdermique contenant de l'alfuzosine.
DE69333594D1 (de) * 1992-09-25 2004-09-23 Synaptic Pharma Corp Für menschliche alpha-1-adrenerge rezeptoren kodierende dns und ihre verwendung
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
EP0865280A1 (en) * 1995-11-15 1998-09-23 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
KR100364328B1 (ko) * 1996-08-29 2002-12-26 사노피-신델라보 알푸조신 염산염의 제어방출 정제
US5922722A (en) * 1996-11-12 1999-07-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
AU5234899A (en) 1998-07-30 2000-02-21 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
AU1808400A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
WO2000029386A1 (en) 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
US20070105880A1 (en) * 2005-11-08 2007-05-10 Torrent Pharmaceuticals Limited Process for the preparation of alfuzosin
US20090069562A1 (en) * 2005-12-26 2009-03-12 Joseph Prabahar Koilpillai Process for the preparation of alfuzosin
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
EP2042179A1 (en) * 2007-09-26 2009-04-01 sanofi-aventis Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
MX361757B (es) 2011-09-19 2018-12-13 Orexo Ab Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides.
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CN113599385B (zh) * 2021-08-20 2023-01-03 兰州大学 阿夫唑嗪在制备治疗糖尿病及其并发症药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2466462A2 (fr) * 1978-02-06 1981-04-10 Synthelabo Derives d'alkylenediamines, leur preparation et leur application en therapeutique
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants

Also Published As

Publication number Publication date
DK246586D0 (da) 1986-05-27
HUT46221A (en) 1988-10-28
EP0204597A2 (fr) 1986-12-10
JPH0564930B2 (enExample) 1993-09-16
ZA863957B (en) 1987-01-28
CA1261755A (en) 1989-09-26
AU586684B2 (en) 1989-07-20
DK168029B1 (da) 1994-01-24
FR2582513B1 (fr) 1988-08-05
IE861395L (en) 1986-11-28
DK246586A (da) 1986-11-29
FR2582513A1 (fr) 1986-12-05
DE3683318D1 (de) 1992-02-20
IL78934A (en) 1991-01-31
EP0204597B1 (fr) 1992-01-08
AU5795186A (en) 1986-12-04
US4661491A (en) 1987-04-28
IL78934A0 (en) 1986-09-30
EP0204597A3 (en) 1989-08-16
IE58595B1 (en) 1993-10-20

Similar Documents

Publication Publication Date Title
JPS61277620A (ja) 排尿困難治療剤
US20080145417A1 (en) Pharmaceutical formulation for the efficient administration apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
EP0946155B1 (en) Pharmaceutical composition for treating fecal incontinence and anal itch
CA2479350A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
ZA200410160B (en) Use of compounds that are effective as selective opiate receptor modulators
JP2007533733A (ja) 食物摂取管理の方法
RS60152B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
US20060035923A1 (en) Overactive bladder treating drug
RU2308268C2 (ru) Производные арил- или гетероарилазолилкарбинолов для лечения недержания мочи
WO2000000187A1 (fr) Compositions medicinales destinees au traitement de l'insuffisance d'evacuation
US20180125792A1 (en) Non-steroidal anti-inflammatory drugs for cough
JP2013199506A (ja) 処置方法
TWI544925B (zh) Stress urinary incontinence and / or therapeutic agents
WO2006115135A1 (ja) 過敏性腸症候群治療剤
JPH08188531A (ja) ビシクロヘプタン誘導体を含む製剤組成物、その製造法、ならびにコレシストキニン系に対する影響に関連する障害の治療のためのその用途
KR100965205B1 (ko) 하부요로 폐색 질환에 따른 축뇨장해의 예방 및/또는치료제
CN110279691B (zh) 一种外科术后护理镇痛药物及其用途
WO2005007191A1 (ja) 医薬組成物
MX2010006520A (es) Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
US9511061B2 (en) Incontinence treatment methods
JP2000026313A (ja) 消化管運動抑制剤
JP2772814B2 (ja) 記憶障害改善剤
Levin et al. Hepatitis associated with iproniazid (Marsilid®) Report of 3 cases

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term